Accessibility & Translations

Fireside Chat on Adolescent Addiction

Product not yet rated

Includes a Live Web Event on 09/24/2026 at 6:00 PM (EDT)

Recorded On: 09/24/2026

  • You must log in to register
    • Non-member - Free!
    • NR Member - Free!
    • NR Associate - Free!
    • NR HSP Credential - Free!
    • NR Practice Academy - Free!
    • CR Associate - Free!
    • CR HSP Credential - Free!
    • International Affiliate - Free!

    Continue

This Program Is Offered In Collaboration With The American Psychological Foundation

APF logo

Description

Dr. Sarah Feldstein Ewing will provide an overview of her body of work relating to adolescent addiction, neuroimaging, and the development of novel interventions and tools for the identification and treatment of adolescent addiction. Drawing on her federally-funded translational research program — which integrates neuroimaging, machine learning, and randomized clinical trials across more than 1,400 youth, Dr. Feldstein Ewing will introduce a novel neurodevelopmental model of adolescent substance use (The Substance use Neuroplasticity And Peer; SNAP Model) and related clinical definition of Adolescent Substance-related Interference and Problems (A-SIP). In addition, Dr. Feldstein Ewing will present the accompanying measurement tool (SIP-IT) and novel substance use treatment grounded in developmental translational (integrated human brain and behavioral) empirical research (Adolescent Developmentally-Appropriate health Promotion Therapy (ADAPT). She will walk attendees through the neurodevelopmental rationale for this shift, how it changes clinical decision-making with teens and families, and how it has been applied and tested internationally, specifically in large-scale randomized controlled trials in Denmark.

Note: This 60-minute webinar starts at 6:00pm Eastern Time. We will share attendee information with the American Psychological Foundation.

Continuing Education Information

1 CE Credit, Instructional Level: Intermediate

1 Contact Hour (New York Board of Psychology)

Disclosures: Presenter has no conflicts of interest to disclose. Generative AI was not used for the development or content of this presentation.

Learning Objectives:

  1. Describe a rationale for the importance of conducting developmental translational research (actively integrating neuroimaging with clinical treatments) with adolescents; specifically, the current gaps in our models, measures, and treatments of adolescent substance use.
  2. Describe a "how-to" for the practical steps involved in conducting developmental translational research with adolescent substance use.
  3. Describe the three novel models, metrics, and treatments that emerged through the developmental translational research for adolescent substance use.
  4. Identify the importance of including underrepresented adolescent populations (youth of color, sexual/gender minority youth) in developmental translational research for adolescent substance use.

----------------------------

CE Disclaimers

The National Register of Health Service Psychologists is approved by the American Psychological Association to sponsor continuing education for psychologists. The National Register maintains responsibility for this program and its content.

The National Register of Health Service Psychologists is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0010

Sarah Feldstein Ewing, PhD

Sarah Feldstein Ewing, PhD

For 2 decades, Dr. Feldstein Ewing has pioneered the integration of neuroimaging with real-world clinical interventions to advance behavioral treatment for adolescents. She has been the first to examine addictions psychotherapy for youth in the imaging environment.

Dr. Feldstein Ewing has produced more than 178 peer-reviewed publications and 4 books from her independent NIH-funded translational studies (including >16 years continuous NIAAA funding as PI). She has enrolled >1,425 unique youth in clinical trials evaluating the neurodevelopmental fit of behavioral therapies, associated neural mechanisms, and treatment outcomes, and applied these findings to create a novel intervention for adolescents (Adolescent Developmentally-Appropriate health Promotion Therapy; ADAPT).

Dr. Feldstein Ewing’s lab is among a handful of those to engage neuroimaging to evaluate the connection between basic brain mechanisms and behavioral treatment outcomes for youth. She has served on the National Academy of Sciences Workgroup for the Health Effects of Cannabis and Cannabinoids (2017), and national/international panels addressing youth brain:behavior translational research and its implications for treatment for adolescents.

You have not yet registered for this course. Register today and access this course any time under "My Courses/Registrations"

Components visible upon registration.